Back to discover
Disease

Coronary Artery Disease

Late-stage therapeutic developmentActively researchedRising momentum
56
Publications
24
Clinical trials
12
Related conditions
2
Related treatments
2025
Latest publication
Current focus
Therapeutic developmentDiagnosis & biomarkersGenetics & risk factorsMetabolic & lifestyle factorsDisease mechanisms & pathology
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

The Role of Stem Cells in the Treatment of Cardiovascular Diseases.

Research2024-03-31International journal of molecular sciences

Approval: Rivaroxaban Accord (EMA)

Regulatory2020-11-16EMA

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Research Highlights1View
Clinical Milestones11View all 11
+3 more in the activity timeline below
Industry & Market1View
Activity timeline13

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Rivaroxabanapproved

Approval — Rivaroxaban Mylan co-administered with acetylsalicylic acid (ASA) alone or with ASA plus… (2021)

Approval — Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the s… (2017)

Cangrelorapproved

Approval — Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reductio… (2015)

Ivabradineapproved

Approval — Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the s… (2015)

Perflutrenapproved

Approval — This medicinal product is for diagnostic use only. Luminity is an ultrasound contrast-enh… (2006)

Research-associated treatments

Clinical trials

16 sponsors · 0 new · 2 completed in the last 12 months (net -2)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies
Recently completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2021emaApprovalRivaroxaban· Rivaroxaban Mylan co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.  Rivaroxaban Mylan co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.  ------ Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.  Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. ------- Adults  Prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ? 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Paediatric population  Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. Paediatric population  Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.   source ↗
2020emaApprovalRivaroxaban· Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients). Adults Prevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ? 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.) Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA) alone or with ASA plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1). Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events. Adults Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ? 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.) Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment. source ↗
2017emaApprovalIvabradine hydrochloride· Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ? 70 bpm. Ivabradine is indicated : - in adults unable to tolerate or with a contra-indication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ? 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated. (see section 5.1) source ↗
2016emaApprovalIvabradine hydrochloride· Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ? 70 bpm. Ivabradine is indicated: in adults unable to tolerate or with a contra-indication to the use of beta-blockers or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ? 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated. source ↗
2015emaApprovalIvabradine· Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ? 70 bpm. Ivabradine is indicated: in adults unable to tolerate or with a contra-indication to the use of beta-blockers or in combination with beta-blockers in patients inadequately controlled with an optimal betablocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ? 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated. source ↗
2015emaApprovalCangrelor· Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable. source ↗
2008emaApprovalRivaroxaban· Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers. Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events. Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Adults Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ? 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment. source ↗
2006emaApprovalPerflutren· This medicinal product is for diagnostic use only. Luminity is an ultrasound contrast-enhancing agent for use in patients in whom non-contrast echocardiography was suboptimal (suboptimal is considered to indicate that at least two of six segments in the 4- or 2-chamber view of the ventricular border were not evaluable) and who have suspected or established coronary artery disease, to provide opacification of cardiac chambers and improvement of left ventricular endocardial border delineation at both rest and stress. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

56 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20102025
Most influential
Recent publications
Major themes8
  • Coronary Artery Disease25
  • Cardiovascular Diseases8
  • Computed Tomography Angiography6
  • Coronary Angiography5
  • Percutaneous Coronary Intervention4
  • Gastrointestinal Microbiome3
  • Plaque, Atherosclerotic3
  • Atrial Fibrillation2
Leading journals6
  • Circulation8
  • European heart journal8
  • The New England journal of medicine6
  • Cardiovascular diabetology2
  • International journal of molecular sciences2
  • Journal of the American College of Cardiology2
Leading researchers8
  • Aragam KG3
  • Bangalore S3
  • Bhatt DL3
  • Blankstein R3
  • Earls JP3
  • Ellinor PT3
  • Greenwood JP3
  • Mehran R3
Affiliations (unnormalised)6
  • Brigham and Women's Hospital7
  • Stanford University School of Medicine5
  • Harvard Medical School4
  • University of Cambridge4
  • University of Oxford4
  • Cardiovascular Research Center3

Related conditions

12 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Coronary artery disease is a pathological process affecting the coronary arteries. It may arise from congenital abnormalities, atherosclerotic disease, or non-atherosclerotic causes. The literature also treats it as a major form of atherosclerotic cardiovascular disease with chronic and acute clinical phases.

Causes

The supplied grounding supports atherosclerosis as a major cause, and also notes that coronary artery disease may derive from congenital abnormality or non-atherosclerotic causes. Chronic kidney disease is described as a major risk factor and is associated with traditional contributors such as diabetes and hypertension. The literature also links smoking and modifiable lifestyle factors to disease risk and prevention.

Pathophysiology

The pathophysiology is described as an inflammatory disorder rather than simply a cholesterol storage disease. Arterial remodeling and nonstenotic plaque biology are emphasized, and plaque disruption can occur even without critical stenosis. Macrophages are highlighted as central to plaque development, local inflammation, and thrombosis, while vascular cell migration and proliferation are also implicated.

Risk factors

Traditional risk factors include diabetes, hypertension, smoking, and other lifestyle-related factors used in risk prediction. Chronic kidney disease is specifically identified as a major risk factor, with additional nontraditional contributors such as inflammation, oxidative stress, and abnormal calcium-phosphorus metabolism. Genetic susceptibility is also supported by genome-wide association findings and polygenic risk score literature.

Current standard of care

Management includes revascularization for relief of ischemia. The literature also supports aggressive management of modifiable risk factors alongside revascularization, and drug therapy is represented by antiplatelet agents such as clopidogrel and ticlopidine. Diagnostic and management approaches also include fractional flow reserve and other diagnostic imaging or diagnostic modalities.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.